| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785276 | Brachytherapy | 2018 | 7 Pages |
Abstract
Degarelix is effective for prostate downsizing before prostate brachytherapy with a median volume decrease of 26.2% by 8 weeks. Despite the short course of treatment and eventual testosterone recovery, follicle-stimulating hormone and luteinizing hormone remain elevated beyond 12 months. Further investigation with randomized comparisons to other hormonal agents is warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M.A. Korzeniowski, J.M. Crook, D. Bowes, M. Gaztañaga, A. Ots, J. Jazwal, J. Rose, A. Tétreault-Laflamme, L. Pilote, R. Halperin, D. Kim, D. Petrik, C. Araujo, F. Bachand,